Features
Tracking
Portfolio tracker
Stock tracker
Dividends
Dividend tracker
Dividend rating
Dividend calendar
Tools
Dividend payout calendar
Ex-dividend calendar
Dividend calculators
Community
Community Hub
Public Portfolios
Popular assets
News & Insights
Pricing
Dark mode
Stocks
Other
Other
RDDA
Dr Reddys Laboratories Ltd
RDDA • STU
€12.10
€0.00
(
0%
)
Overview
Dividends
Financials
News
Community
Estimate
P/E
39
EPS
0.31
Beta
0.366
Growth
Revenue, YoY
-12.21%
Net income, YoY
-70.92%
FCF, YoY
-196%
Dividends
Dividend yield
0.61%
Annual payout
€0.07
Next ex. div date
July 9, 27
Payout
20.34%
Div.growth, 5y
6.53%
Div.rating
About the company
Ticker
RDDA
ISIN
US2561352038
Country
Other
Sector (GICS)
Other
Frequently asked questions
What sector does Dr Reddys Laboratories Ltd (RDDA) operate in?
Dr Reddys Laboratories Ltd belongs to the Other sector.
What is Dr Reddys Laboratories Ltd (RDDA) current stock price?
As of the latest data, Dr Reddys Laboratories Ltd stock price is €12.10, with a previous close of €12.10.
What is Dr Reddys Laboratories Ltd (RDDA) Earnings Per Share (EPS)?
The trailing EPS is €0.31.
What is Dr Reddys Laboratories Ltd (RDDA) Price-to-Earnings (P/E) ratio?
Dr Reddys Laboratories Ltd current P/E ratio is 39.03.
What is Dr Reddys Laboratories Ltd (RDDA) EBITDA?
Dr Reddys Laboratories Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 112.40 million.
Does Dr Reddys Laboratories Ltd (RDDA) pay dividends?
Yes. Dr Reddys Laboratories Ltd pays annual dividends with an annualized yield of 0.61% and an estimated annual payout of €0.07 per share.
When is the next ex-dividend date for Dr Reddys Laboratories Ltd (RDDA)?
The next ex-dividend date is scheduled for July 09, 2027.
When is Dr Reddys Laboratories Ltd (RDDA) next earnings report?
Dr Reddys Laboratories Ltd is expected to release its next earnings report on September 30, 2026.
What is Dr Reddys Laboratories Ltd (RDDA) beta (volatility) score?
Dr Reddys Laboratories Ltd has a beta of 0.366, indicating lower volatility than the overall market.